ANDA 84921, held by Abraxis Pharm. Hydroxocobalamin.
As of Nov 13, 2026, ANDA 84921 (Hydroxocobalamin), held by Abraxis Pharm, was not approved, with 4 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxocobalamin1MG/ML ยท injectable;injection | Hydroxocobalamin | Discontinued |
| Dec 7, 1984 | Supplement 8Manufacturing | Approved | None posted |
| Sep 14, 1984 | Supplement 7Manufacturing | Approved | None posted |
| Mar 13, 1984 | Supplement 6Manufacturing | Approved | None posted |
| Jun 15, 1982 | Supplement 4Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
